GSK

GSK (NYSE: GSK), formerly GlaxoSmithKline, is a multinational biopharmaceutical company that discovers, develops, and manufactures Specialty Medicines, General Medicines, and Vaccines. . In July 2022, the company completed its largest corporate restructuring in 20 years, demerging its consumer healthcare division and forming two new separate entities (GSK and Haleon). Following the spin-off, GSK retained 13% ownership of Haleon as a short-term financial investment, and GSK began focusing solely on its biopharma business from Q2 2022. 

GSK develops and commercializes Specialty Medicines, covering four primary therapeutic areas: respiratory, HIV, immuno-inflammation, and oncology. This also includes a COVID-19 solution (Xevudy), which was developed through a partnership with Vir Biotechnology. The pharma giant’s newly defined General Medicines portfolio consists of primary care brands such as Trelegy as well as other established and mature prescription medicines. Furthermore, GSK develops Vaccines mainly targeting infectious diseases using a technology-driven approach to identifying pathogens. As of 2024, GSK had over 20 marketed vaccines with an annual sales volume of over half a billion doses worldwide. GSK's R&D pipeline at the end of Q4 2023 consisted of 71 vaccines and medicines in development.

More than 50% of GSK’s group sales came from the US market during FY2023, where it intends to concentrate its efforts on Vaccines and Specialty Medicines sales in the region. The company's top priority is advancing its late-stage pipeline and enhancing its early-stage research and technological capabilities. The company is planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory, and oncology. Also, based on the favorable financial performance in FY2023, the company upgraded its growth outlooks for 2026 and 2031.